Shortcut to Body
  1. HOME
  2. All KODEX ETFs
  3. Product Details

Asset type Foreign Equity Sector

KODEX SYNTH-US Biotech(185680)

The most effective way to invest in the fast-growing industry, Biotechnology.
KODEX Synth-US bio mainly focuses on USA's biotechnology companies committed to healthier future.

Last data obtained Quotes delayed at least 20 minutes. Market data provided by KOSCOM.

  • Current Price (KRW)


    down 50 (-0.18%)

  • iNAV (KRW)


    up 54 (0.19%)

  • Trading Volume (shares)


About Product

* as of Aug 12, 2020

Benchmark Index

S&P Biotechnology Select Industry Index(KRW)

The S&P Biotechnology Select Sector Index seeks to track the Biotechnology sector - stock classifications are based on the Global Industry Classification Standard (GICS).

View index information in detail

Key Facts

Basic Information - Net Assets, Benchmark Index, Gross Expense Ratio, Dividend, Benchmark Index, Base Currency, General Administrator, Trustee
Net Assets 15 (billion) Base Currency KRW
Inception Date October 31, 2013 General
Gross Expense
(AP : 0.020%, Manager fee : 0.190%, Trustee Fee : 0.020%, General Administrator Fee : 0.020%)
Trustee KB Bank
Dividend No dividend distribution Related
  • Carefully consider the Funds' investment objectives, risk factors, and charges and expenses before investing.
  • Collective investment schemes are not insured by the Korea Deposit Insurance Corporation.
  • The performance quoted represents past performance and does not guarantee future results.
  • Investment return and principal value will fluctuate, so you may have a gain or loss when shares are sold.
  • Current performance may be lower or higher than the performance quoted.
  • This information is not warranted to be accurate, complete, or timely.
  • Neither KOSCOM nor Samsung Asset Management is responsible for any damages or losses arising from any use of the information on this website.
  • This website is made in the Korean language, and if there shall arise any conflict between the Korean version and any translation thereof,
    including this -English translation, the Korean version shall prevail.

Samsung Asset Managementcompliance review No.2018-189 (2018.05.21)